

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

EPI-ASTHMA study protocol - a population-based multicentre stepwise study on the prevalence and characterisation of patients with asthma according to disease severity in Portugal

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-064538
Article Type:	Protocol
Date Submitted by the Author:	10-May-2022
Complete List of Authors:	Jácome, Cristina; Center for Health Technology and Services Research Brito, Dinis; USF 7fontes João, Catarina; University of Porto, Lopes, Filipa; MEDIDA Santos, Janete; Center for Health Technology and Services Research Amorim, Liliana; Digital Medicine Center P5 Barbosa, Maria João; University of Minho; Gualtar Family Health Unit Pardal, Marisa; AstraZeneca Teixeira, Pedro; University of Minho - Gualtar Campus, Bernardo, Filipa; AstraZeneca Fonseca, Joao A.; University of Porto Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit,
Keywords:	Asthma < THORACIC MEDICINE, EPIDEMIOLOGY, Chronic airways disease < THORACIC MEDICINE

SCHOLARONE[™] Manuscripts

3		
4 5	1	EPI-ASTHMA study protocol - a population-based multicentre stepwise study on
6 7	2	the prevalence and characterisation of patients with asthma according to
8 9	3	disease severity in Portugal
10 11	4	Cristina Jácome ^{1,2} , Dinis Brito ^{3,4} Catarina João ¹ , Filipa Lopes ⁵ , Janete Santos ¹ , Liliana
12 13	5	Amorim ⁶ , Maria João Barbosa ^{3,9} , Marisa Pardal ⁷ , Pedro Teixeira ^{3,6} , Filipa Bernardo ⁷ ,
14 15	6	João Almeida Fonseca ^{1,2,5,8} , Jaime Correia de Sousa ³
16 17	7	
18 19 20	8	Affiliations:
21 22	9	1- Center for Health Technology and Services Research (CINTESIS), Faculty of
23 24 25	10	Medicine, University of Porto, Porto, Portugal;
26 27	11	2- Department of Community Medicine, Information and Health Decision Sciences
28 29 30	12	(MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal
31 32	13	3- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of
33 34 35	14	Minho, Braga, Portugal
36 37	15	4- Sete Fontes, Family Health Unit, Braga, Portugal
38 39 40	16	5- MEDIDA, Porto, Portugal
41 42 43	17	6- Digital Medicine Center P5, Braga, Portugal
44 45 46	18	7- AstraZeneca, Queluz, Lisboa, Portugal
47 48	19	8- Allergy Unit, Hospital and Institute CUF, Porto, Portugal
49 50 51	20	9-Gualtar Family Health Unit, Braga, Portugal
52 53 54	21	Corresponding author: Cristina Jácome; Center for Health Technology and Services
55 56	22	Research (CINTESIS), Department of Community Medicine, Information and Health
57 58	23	Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Portugal; e-
59 60	24	mail: cristinajacome.ft@gmail.com

ABSTRACT Introduction: In Portugal as in other countries, data on the epidemiology of asthma are mainly grounded in questionnaire studies. Additionally, the detailed characterisation of asthma in terms of disease severity, control and phenotypes remain scarce. Studies assessing the prevalence of asthma and its sub-groups using accurate methods are needed. This study aims to determine the prevalence of asthma, difficult-to-treat and severe asthma, and to evaluate sociodemographic and clinical characteristics of those patients, in mainland Portugal. Methods and analysis: A population-based nationwide study with a multicentre stepwise approach will be conducted between 2021-2023 in 38 primary care centres of the Portuguese National Health Service. The stepwise approach will comprise 4 Stages: Stage 0-telephone call invitation to adult subjects (≥18 years) randomly selected (n~15000); Stage 1-telephone screening interview assessing the participants' respiratory symptoms (n~7500); Stage 2- diagnostic visit, including physical examination, diagnostic tests (e.g., spirometry, fraction of exhaled nitric oxide, blood eosinophil count), and patient-reported outcome measures for diagnostic confirmation of those identified with possible asthma at Stage 1 (n~1800); Stage 3-further evaluation of patients with asthma and of patients with difficult-to-treat asthma and severe asthma, after 3 months ($n\sim460$). At Stage 3, data will be collected from a review of the patient's electronic health records, a follow-up telephone call and the CARATm app database. The prevalence of asthma, difficult-to-treat and severe asthma will be determined as the percentage of patients with asthma confirmed from the overall population (Stage 1). For the analysis of factors associated with asthma, difficult-to-treat and severe asthma, logistic regression models will be explored.

Ethics and dissemination: Ethical approvals for the study were obtained from the 51 ethics committee of the local health unit of Matosinhos, Porto (38/CES/JAS), Alto Minho

BMJ Open

3	52	(38/2021/CES) and the regional health administration of Lisbon-Vale do Tejo
5	53	(035/CES/INV/2021). Results will be published in peer-reviewed journals.
7 8	54	
9 10 11	55	Trial registration: ClinicalTrials.gov, NCT051696198. Registered at 27 th December 2022.
12 13	56	
14 15 16	57	Strengths and limitations of this study
17 18	58	- EPI-ASTHMA is the first national population-based study with a multicentre stepwise
19 20	59	approach to determine the prevalence of asthma, difficult-to-treat and severe asthma In
21 22 23	60	Portugal.
24 25	61	- The outcome measures will enable a more comprehensive characterisation of patients
26 27	62	with asthma and a better understanding of their disease characteristics, treatment
28 29 30	63	patterns and use of healthcare resources.
31 32	64	- The knowledge generated by this study has great potential to inform health policies and
33 34	65	to improve the clinical outcomes of patients with asthma in Portugal.
35 36	66	- Time limited follow-up with lack of optimised management might be a source of error
37 38 39	67	in the estimation of the prevalence of asthma sub-groups.
40 41	68	- Heterogeneity in data collection across the country conveniently select regions may
42 43 44	69	prove challenging and a source of bias.
45 46 47	70	Keywords: disease severity, severe asthma, difficult-to-treat asthma, epidemiology
48 49	71	
50 51 52	72	
53 54	73	
55 56 57 58 59 60	74	

75 Introduction

Asthma is a common chronic disease affecting all age groups. Worldwide, it is estimated that about 5 to 10% of people have asthma [1], with a significant wide variation across regions and countries [2]. To date, epidemiological data on prevalence have used heterogeneous methodologies due to difficulties in defining and diagnosing asthma, leading to highly variable estimates of asthma prevalence [3]. Some studies used non-standardised questionnaires, others included participants based on the assessment of lung function or responsiveness to bronchodilators. In Portugal, the 2011 National Asthma Survey was based on telephone interviews and indicated a prevalence of 6.8% [4]. Yet, previous studies have estimated a prevalence between 3.3 and 15% [5]. Furthermore, similarly to the USA and Denmark Asthma Surveys, the 2005-2006 Portuguese Health Survey, suggested that there is an underdiagnosis of asthma, particularly in the male population and in the country's southern regions [5]. The Portuguese National Program for Respiratory Diseases maintains strategic research objectives in epidemiological surveillance both in asthma prevalence and its underdiagnosis [6], which is in line with the recommendations from the Global Initiative for Asthma (GINA) [7].

Additionally, national data on the characterisation of patients with asthma, in terms of severity and control, remain lacking [8]. Worldwide, it is estimated that up to 17% of patients have difficult-to-treat and 3.7% have severe asthma [9], which are more likely to experience life-threatening exacerbations and consume additional healthcare resources. It is important to differentiate these severity groups, as difficult-to-treat asthma might be manageable in primary health care, eventually with concomitant support from a secondary care specialist, whereas severe asthma requires a specialised second or tertiary care approach [10]. Knowledge on the distribution of severity and characteristics of patients in each group will better support clinical management of the disease and will

BMJ Open

2	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
23 24	
24	
25 26	
26	
27	
28	
29	
30	
31	
32	
33	
24	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
55 56	
57	
58	
59	
60	

102 inform personalised health policies for a future and smarter allocation of healthcare103 resources.

104 The primary aim of this study is to determine the prevalence of asthma, difficult-to-treat 105 and severe asthma in Portugal. The secondary aims are to evaluate the 106 sociodemographic and clinical characteristics of patients with asthma.

108 METHODS AND ANALYSIS

109 Patient and Public Involvement

110 No patient involved

111 Study Design

107

112 EPI-ASTHMA is a population-based, nationwide, cross-sectional, prevalence study. This study will be conducted between 2021 and 2023, and will involve 38 primary care centres 113 (PCC) of the Portuguese National Health Service (NHS), geographically distributed 114 across all mainland Portugal Health Regions (North, Centre, Lisbon Metropolitan Area, 115 Alentejo and Algarve). EPI-ASTHMA will be first piloted in one local health unit located 116 117 in the North region, where all study procedures will be tested; after that, it will follow the order of approval of the ethics committee from each local health unit and regional health 118 administrations. The study will be conducted using a stepwise approach parallel to a 119 120 clinical practice diagnostic methodology. Firstly, subjects will be invited for a screening 121 telephone interview to report respiratory symptoms, those who fulfil the eligible criteria 122 will be invited for a clinical assessment in a mobile outpatient clinic. A sub-group of participants with confirmed asthma diagnosis will have a follow-up after 3 months for 123 124 characterization of their asthma profile, symptoms patterns, clinical features, and treatment patterns. This study protocol is described according to STROBE (The 125 Strengthening the Reporting of Observational Studies in Epidemiology Statement: 126 guidelines for reporting observational studies)[11]. 127

 $n = \frac{Z^2 P(1-P)}{d^2}$ (1)

128 Study population and sample size

129 Sample size was estimated using Cochran's formula [12]:

Where *n* is the sample size, *Z* is the statistic corresponding to level of confidence, *P* is expected prevalence of Severe Asthma, and d is the desired level of precision (i.e. the margin of error). Applying a Z = 1.96 (i.e. 95% confidence interval), an estimated prevalence in the population of P = 0.42% and a margin of error of 0.15% the estimated sample size is 7141. In order to obtain 7500 participants on screening we consider a stepwise approach with a 50% dropout on invitation. Therefore, around 15000 adults will be randomly selected from the Portuguese NHS database to be contacted and invited to enrol in the study. In Portugal, the majority of the population (including Portuguese nationals and legal residents) is registered in a PCC, therefore the NHS database includes almost the entire resident population in the local administrative entity (i.e., Nomenclature of Territorial Units for Statistics-NUTS). The sample stratification was based on demographic stratification NUTS III, small regions for specific diagnoses as per EUROSTAT classification. For each NUTS III, the PCC were selected according to the feasibility of implementing the study (in total 38 PCC, 31 are part of the regional health administrations and 7 of local health units). The number of participants will be randomly selected according to the proportional allocation of each PCC. The distribution of an estimated stratified sample by NUTS III and the correspondent study Stages is presented in Table 1. The study will include male or female subjects with at least 18 years old, registered in the NHS database, who give voluntary consent. Subjects with any specific physical and/or cognitive disabilities that prevented them from cooperating with the study procedures (e.g., lung function tests) and/or understanding/answering self-reported questionnaires will be excluded.

154 Table 1 – Distribution of the estimated stratified sample [13].

NUTS III	Population	Primary	Stage 0	Stage 1	Stage 2	Stage
		care	(0.15%)	(50%)	(24%)	(25%)
		centres				
Alto Minho/Cávado	637305	2	975	488	118	30
Ave	414763	2	635	317	77	19
Área Metropolitana do	1719362	6	2631	1316	319	81
Porto						
Alto Tâmega/Douro/Terras	389151	2	596	298	72	18
de Trás-os-Montes						
Tâmega e Sousa	419811	2	643	321	78	20
Oeste	357868	2	548	274	66	17
Região de Aveiro	363424	2	556	278	67	17
Região de Coimbra	438228	2	671	335	81	21
Região de Leiria	287040	1	439	220	53	13
Viseu Dão	555628	2	850	425	103	26
Lafões/Beiras/Serra da						
Estrela/Beira Baixa						
Médio Tejo/Lezíria do Tejo	474802	2	727	363	88	22
Área Metropolitana de	2827514	9	4328	2164	525	133
Lisboa						
Alentejo Litoral/Baixo	475674	2	728	364	88	22
Alentejo/Alto Alentejo/						
Alentejo Central						
Algarve	440543	2	674	337	82	21
Total	9801113	38	15000	7500	1819	460

156 Study procedures

EPI-ASTHMA will use a stepwise approach, sequentially comprising the evaluation of
symptoms patterns, clinical features, and tests for diagnosis confirmation, that includes
the following stages (Figure 1):

• Stage 0- Study enrolment: Telephone call invitation to enrol participants;

- Stage 1- Screening interview: Telephone call interview to assess respiratory
 symptoms;
 - Stage 2- Diagnostic visit: Clinical assessment, diagnostic confirmation and
 patient characterization;
- Stage 3- Sub-group asthma characterization: follow-up of patients with
 asthma (sub-group) and of patients with difficult-to-treat asthma and severe
 asthma, after 3 months.
- 168 Stage 0- Study enrolment

Around 15,000 randomised subjects 18 years or above will receive a telephone call invitation for enrolment in the study, to secure a sample size of 7500 participants for the next stage (assuming an acceptance of 50%)[14]. If needed, a second round of telephone calls will also be made to complete the number of patients in each region. Trained clinical secretaries will conduct this stage by following a semi-structured guide during the telephone call. A screening log of potential eligible participants will be completed to document the main reasons for participants not entering the study. Subjects who fulfil the study eligibility criteria and give their oral consent will be contacted in Stage 1.

178 Stage 1- Screening interview

A computer-assisted telephone screening interview will be performed to 7500 participants. The interview will include validated patient-reported outcome measures for screening asthma [15] and chronic obstructive pulmonary disease (COPD) [16], dysphoea [17] and assessment of physical activity [18,19], among other questions formulated by the researchers (Table 2). At this stage participants will be considered eligible and invited to participate in Stage 2 if they have, at least, one positive response in the Adult Asthma Score (A2 Score) [15], i.e., medical history of asthma or asthma medication intake or asthma symptoms. For quality control, 5% of not eligible participants (with a negative score) will also be invited to participate in Stage 2. Interviews will be

Page 9 of 20

 BMJ Open

performed by a centralised team of trained and experienced interviewers. Each participant will be contacted for at least ten attempts during different occasions before being considered excluded. Prior to any question, participants will be asked to reinforce their oral consent to participate. A pilot study with 12 individuals was conducted to assess the clarity and feasibility of the screening interview before starting the data collection [20]. The duration of each interview was no longer than 17 minutes.

The diagnostic visit will be conducted in a mobile outpatient clinic, located, whenever

194 Stage 2 – Diagnostic visit

possible, in the close vicinity of each PCC. At this stage, participants will give a written informed consent before any study-related procedures. Stage 2 is expected to include 1800 participants, about 20% of participants from Stage 1 who fulfil the eligibility criteria, plus 5% of participants for quality control. A detailed clinical assessment will be performed, including clinical history, physical examination, lung function tests, blood count and inflammatory biomarkers testing and patient-reported outcome measures (Table 2). The clinical assessment will be carried out by a physician and the diagnostic tests by an experienced team to assure the quality and the harmonisation of procedures. All patients will be provided with a letter addressed to their primary care physician, containing the results of their clinical evaluation. Patients with asthma will also be invited to install and use the CARATm app ("Caracteristicas Auto-reportadas de Asma em Tecnologias Móveis") in their daily life. CARATm is a Portuguese health mobile app developed to collect clinical data from patients with asthma, such as asthma control and medication adherence, which is also interoperable with the Portuguese Severe Asthma

212 Stage 3- Sub-group asthma characterization

Registry (asmagrave.pt).

213 This stage is expected to include 460 participants: a randomised sample of patients with 214 asthma, and all patients identified with difficult-to-treat or severe asthma. Patients with

difficult-to-treat and severe asthma will be defined according to GINA[21]. This stage takes place 3-months after the diagnostic visit and consists of a review of patients' electronic health records, a follow-up telephone call to the patient, and extraction of CARATm app data. The review of patients' electronic health records by a physician of their PCC will ensure an asthma control assessment on two different time points, and will confirm the treatment profile for an adequate GINA severity classification [7] (Table 2).

_

Table 2. Summary of the data collection per study's stage.

	Stage 1	Stage 2	Stage 3
Sociodemographic and anthropometric characteristics	×		
Brief PA assessment	×	×	
Respiratory symptoms (wheeze, breathlessness)	×	×	×
CAPTURE	×		
mMRC	×		
Diagnosis of chronic respiratory disease	×	×	×
Comorbidities and allergies	×	×	×
Smoking habits and ETS	×	×	
A2 Score	×		
Family history of asthma	×	×	
Age of asthma onset		×	
Inhaler prescription/use	×		
Mini-AQLQ		×	
EQ-5D		×	
Signs of asthma		×	
CARAT		×	×
Asthma control (according to GINA)		×	×
Asthma pharmacological treatment		×	×*
Inhalation technique		×	
Adherence to inhaled medication		×	×*
Other treatments		×	×
Number of exacerbations		×	×*
Number of visits to emergency room		×	×*

Number of hospital admissions and length of hospital stay		×	×*
Number of unscheduled consultations		×	×*
Number of consultations primary care team		×	×*
Referral for specialist care		×	×*
Standard measurements (blood pressure, height, weight)		×	
Pre-BD and post-BD lung function		×	
Pulmonary diagnostic tests (previously performed)			×
FeNO		×	
Peripheral blood eosinophil and neutrophil counts		×	
Use of health and fitness apps	×	×	
CARATm app use and opinion			×

A2 Score= A2 adult asthma score[15]; CAPTURE= COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk [16]; mMRC=Modified British Medical Research Council [17];PA = Brief physical activity assessment [18,19]; Mini-AQLQ=Mini Asthma Quality of Life Questionnaire[22,23]; EQ-5D=European Quality of Life Five Dimension [24];CARAT=Control of Allergic Rhinitis and Asthma Test [25]; pre-BD and post-BD=Spirometry pre- and post-bronchodilator [26]; FeNO=Fractional exhaled nitric oxide [27]; || *In the previous 3 and 12 months.

226 Data storage, blinding and statistical analysis plan

Participants will be anonymized with a unique subject ID and their data will be anonymously stored in an appropriately secured server. In order to minimise diagnostic bias, researchers, data collectors and participants will be blinded to patient eligibility throughout data collection during Stage 2. Over the stages, data will be collected for a specific electronic case report form (e-CRF) by using blended data (primary and secondary data).

Statistical analysis will allow the characterization of the study population and the estimation of each study's endpoints. The prevalence of asthma, difficult-to-treat and severe asthma with the respective 95% confidence intervals (95% CI) will be calculated in relation to the entire study population (Stage 1). Descriptive statistics such as i) central tendency (e.g. mode, median or mean); ii) localisation (e.g. percentile); iii) dispersion (e.g. interquartile range, standard deviation) and iv) distribution (e.g. skewness, kurtosis) will be used, depending on the type of each variable, to characterise the total sample or

> subgroups. Associations between two quantitative variables will be calculated using the Pearson's correlation coefficient or Spearman correlation coefficient, in case of normality assumption are not verified. Association of two categorical variables will be determined using the Chi-Square test or Fisher Exact test. Continuous variables between two groups will be compared with a t-test for independent samples or Mann-Whitney test, whereas for comparisons among 3 or more groups an ANOVA or Kruskall-Wallis test will be used. Null-hypothesis statistical testing will also be applied in an exploratory manner to identify any relationship patterns among variables. Subgroup analysis per each asthma control level, GINA treatment step, Short-Acting Beta Agonists (SABA) overuse among others, will also be conducted. Measurements of effect size will be presented and confidence intervals at 95% will be estimated to account for the uncertainty of the sample estimates. Interim analysis will be conducted per region after all stages are completed.

For the analysis of factors associated with asthma, difficult-to-treat asthma and severe asthma, logistic regression models will be explored, taking into consideration these as dependent variables and sociodemographic, clinical, among other variables, as independent variables. The variables to be included in the multivariate model will be selected from the univariate analyses, when p-value <0.100, those that do not meet these criteria, but are considered clinically relevant, will also be possible candidates. The final model will be analysed from two perspectives: 1) the calibration using the Hosmer-Lemeshow goodness of fit test, and 2) the discrimination, using ROC curves and the respective area under the curve. All results will be considered statistically significant when p-value < 0.05.

DISCUSSION

Page 13 of 20

BMJ Open

The EPI-ASTHMA study will address knowledge gaps in the epidemiology and characterisation of asthma in mainland Portugal, using a multicentre approach that combines different data collection methods, including a mHealth solution. Furthermore, it will provide a more complete picture of the prevalence of difficult-to-treat and severe asthma in Portugal, and will allow a better understanding of these patients' characteristics, treatment profile and healthcare resource use. Further knowledge on the distribution of severity and characteristics of patients in each group will better support clinical management of the disease and inform personalised health policies for a smarter allocation of the needed healthcare resources. This ambitious study is aligned with the global need of epidemiological studies to monitor the trends in the prevalence of asthma, which is vital to ensure that health policies fit the populations' needs [2,28,29].

The study design is one of its strengths. The combination of standardised questionnaires with a standardised clinical evaluation, including lung function tests will allow a more accurate diagnosis and characterisation of asthma. However, few limitations and potential risks must be acknowledged. The definition of difficult-to-treat and severe asthma will be based on the GINA treatment steps (4-5) and the assessment of asthma control during the study Stages 2 and 3, which is only 3-months apart. An optimised management during the follow-up period was not included, which is also part of the GINA criteria to distinguish these asthma subgroups. This will probably be a source of error in the estimation of the prevalence of these sub-groups, linked to the observational nature of this study. The 38 PCC will be conveniently selected, which can be seen as a source of bias. Yet, we considered the geographic areas and population distribution of each Portuguese region as well as their interest to participate and willingness to collect data and not only based on previous asthma research experience which will preserve the study real-world nature. Clinical secretaries (Stage 0) and physicians (Stage 2 and 3) will collaborate across different country's regions, which may introduce some heterogeneity in data collection. Nevertheless, both clinical secretaries and physicians will be previously trained and continuously motivated by the management team, which will be available to clarify doubts on a 24/7 basis. To deal with possible risks, the study's steering committee will supervise the execution and will take academic responsibility for the study. Another limitation is the need for this multicentre study to be approved by the ethics committees responsible for each regional health administration/local health unit. Although all applications will be similar in their content, they will differ in a number of aspects to comply with each institution's formal requirements, resulting in additional complexity and may hinder the compliance with the study timeline. To mitigate these risks, an experienced contracted research organisation that knows the specificities of each administration/health unit is supporting us through all the process.

EPI-ASTHMA will be managed combining traditional management methodologies with an "agile" approach [30] using the SCRUM framework on Jira software. This combination is expected to fulfil the need to make the study adaptable and to anticipate future needs that are important and can be forgotten due to the dimension of the study.

Conclusion

EPI-ASTHMA will be the first population-based study in Portugal to determine the prevalence of asthma, difficult-to-treat and severe asthma and to better understand the patient's disease characteristics, treatment patterns and use of healthcare resources. The knowledge generated by this nationwide robust study has great potential to inform health policies and to improve the clinical outcomes of patients with asthma in Portugal.

Ethics and dissemination:

The study will follow the tenants of the Declaration of Helsinki and the Oviedo Convention. Ethical approvals and data privacy clearance for the study were obtained by the Ethics Committee and Data Protection Officer of the local health unit of Matosinhos, Porto (ULSM: 38/CES/JAS, March 12th .2021), Alto Minho (ULSAM: 38/2021/CES, June 17th, 2021) and the Regional Health Administration of Lisbon and

1 2		
2 3 4	319	Vale do Tejo (ARSLVT; 035/CES/INV/2021; December 3rd 2021) and is under revision
5 6	320	in the remain regional ethical committees for health administration/local health units. All
7 8	321	participants will received both verbal and written information explaining the purpose of
9 10	322	the study and they will have to provided verbal and written informed consent. Results will
11 12	323	be presented at both national and international scientific meetings and published in peer-
13 14	324	reviewed journals. Seasonal newsletters will be provided to the funders of the study as
15 16	325	well as all the involved participants.
17 18 19	326	
20 21 22	327	Statements
23 24 25	328	Patient consent for publication
26 27	329	Not applicable.
28 29 30	330	
31 32	331	Authors' contributions
33 34	332	JCA, JAF and FB conceptualised the study. CJ wrote the statistical analysis plan and
35 36 37	333	PT conducted the sample size calculation. CJ and CJO wrote the first draft of the
38 39	334	manuscript. All authors contributed to and refined the manuscript for scientific content.
40 41	335	All authors read and approved the final version of the manuscript.
42 43 44	336	
45 46 47	337	Competing interests
48 49	338	JCS reports Advisory Board from Boheringer Ingelheim, personal fees and Advisory
50 51	339	Board from GSK, grants, personal fees and Advisory Board from AstraZeneca, personal
52 53	340	fees and Advisory Board from Bial, non-financial support from Mundipharma, personal
54 55	341	fees from Sanofi, Advisory Board from Novartis, outside the submitted work. JAF
56 57 58	342	declares grants from or research agreements with AstraZeneca, Mundipharma, Sanofi
58 59 60	343	Regeneron and Novartis. Personal fees for lectures and attending advisory boards from

2	
3	
4	
5	
6	
7	
8	
9	
10	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
∠∪ ว1	
21	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24 25 26 27 28 29 30	
23	
24	
25	
26	
27	
28	
20	
29	
30	
 31 32 33 34 35 36 37 38 	
32	
33	
34	
35	
36	
37	
20	
39	
40	
41	
42	
43	
44	
45	
46	
47	
47	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

AstraZeneca, GSK, Mundipharma, Novartis, Sanofi Regeneron and TEVA. MP and FB
are employees of AstraZeneca, Produtos Farmacêuticos. The remaining authors declare
no conflicts of interest.

347

348

1

349 Funding for this study was provided by AstraZeneca. N/A for the award/grant number.

350

351 **REFERENCES**

Funding

Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International
 ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur
 Respir J. 2014;43: 343–373.

Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma
 prevalence. Eur Respir J. 2020;56.

357 3. Sá-Sousa A, Jacinto T, Azevedo LF, Morais-Almeida M, Robalo-Cordeiro C,

358 Bugalho-Almeida A, et al. Operational definitions of asthma in recent

359 epidemiological studies are inconsistent. Clin Transl Allergy. 2014;4: 24.

360 4. Sa-Sousa A, Morais-Almeida M, Azevedo LF, Carvalho R, Jacinto T, Todo-Bom A,

et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey.
Clin Transl Allergy. 2012;2:15.

363 5. de Sousa JC, Santo ME, Colaço T, Almada-Lobo F, Yaphe J. Asthma in an urban
 364 population in Portugal: a prevalence study. BMC Public Health. 2011;11: 347.

365 doi:10.1186/1471-2458-11-347

366 6. da Saúde D-G. Programa Nacional para as Doenças Respiratórias 2017. Lisboa:
 367 Direção-Geral da Saúde; 2017.

Page 17 of 20


BMJ Open

1			
2 3	368	7.	Global Initiative for Asthma. Global Strategy for Asthma Management and
4 5 6 7	369		Prevention. 2021. Available on the GINA website: <u>https://ginasthma.org/</u>
7 8 9	370	8.	Sá-Sousa A, Amaral R, Morais-Almeida M, Araújo L, Azevedo LF, Bugalho-
10 11	371		Almeida A, et al. Asthma control in the Portuguese National Asthma Survey. Rev
12 13 14	372		Port Pneumol. 2015;21: 209–213.
15 16	373	9.	Narasimhan K. Difficult to Treat and Severe Asthma: Management Strategies. Am
17 18	374		Fam Physician. 2021;103: 286–290.
19 20 21	375	10.	Ryan D, Murphy A, Ställberg B, Baxter N, Heaney LG. "SIMPLES": a structured
22 23	376		primary care approach to adults with difficult asthma. Prim Care Respir J. 2013;22:
24 25 26	377		365–373.
20 27 28 29	378	11.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et
30 31	379		al. The Strengthening the Reporting of Observational Studies in Epidemiology
32 33	380		(STROBE) statement: guidelines for reporting observational studies.
34 35 36	381		Epidemiology. 2007;18: 800–804.
37 38	382	12.	Kasiulevičius V, Šapoka V, Filipavičiūtė R. Sample size calculation in
39 40 41	383		epidemiological studies. Gerontologija. 2006;7: 225-231.
42 43	384	13.	Instituto Nacional de Estatística. Censos 2011. XV Recenseamento Geral da
44 45	385		População: V Recenseamento Geral da Habitação. Resultados definitivos:
46 47	386		Portugal. Lisboa: INE, 2012. IV Recenseamento Geral de Habitação. Lisboa,
48 49 50	387		Portugal: Instituto Nacional de Estatistica; 2012.
51 52	388	14.	Lopes C, Torres D, Oliveira A, Severo M, Alarcão V, Guiomar S, et al. Inquérito
53 54	389		Alimentar Nacional e de Atividade Física IAN-AF 2015-2016: relatório de
55 56 57	390		resultados. 2017.
58 59 60	391	15.	Sá-Sousa A, Pereira AM, Almeida R, Araújo L, Couto M, Jacinto T, et al. Adult

2 3 4	392		Asthma Scores-Development and Validation of Multivariable Scores to Identify
5 6 7	393		Asthma in Surveys. J Allergy Clin Immunol Pract. 2019;7: 183–190.e6.
, 8 9	394	16.	Martinez FJ, Mannino D, Leidy NK, Malley KG, Bacci ED, Barr RG, et al. A New
10 11	395		Approach for Identifying Patients with Undiagnosed Chronic Obstructive
12 13 14	396		Pulmonary Disease. Am J Respir Crit Care Med. 2017;195: 748–756.
15 16	397	17.	Standardized Questionaries on Respiratory Symptoms. Br Med J. 1960;2: 1665–
17 18 19	398		1665.
20 21	399	18.	Cruz J, Jácome C, Oliveira A, Paixão C, Rebelo P, Flora S, et al. Construct validity
22 23 24	400		of the brief physical activity assessment tool for clinical use in COPD. Clin Respir
25 26	401		J. 2021;15: 530–539.
27 28 29	402	19.	Marshall AL, Smith BJ, Bauman AE, Kaur S. Reliability and validity of a brief
30 31	403		physical activity assessment for use by family doctors. Br J Sports Med. 2005;39:
32 33 34	404		294–7; discussion 294–7.
35 36	405	20.	van Teijlingen E, Hundley V. The importance of pilot studies. Nurs Stand. 2002;16:
37 38 39	406		33–36.
40 41	407	21.	Global Initiative for Asthma. A new Pocket Guide, "Diagnosis and Management of
42 43	408		Difficult-to-treat and Severe Asthma in adolescent and adult patients.", 2021.
44 45 46	409		Available on the GINA website: <u>https://ginasthma.org/</u>
47 48	410	22.	Ferreira PL, Mendonça C, Newparth N, Mata p, Juniper EF, Mear I. Quality of life
49 50	411		in asthma: cultural adaptation of Juniper's AQLQ to Portuguese. 1998. p.7 (7):
51 52 53	412		590.
54 55 56	413	23.	Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation
56 57 58	414		of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14: 32–38.
59 60	415	24.	Ferreira PL, Ferreira LN, Pereira LN. Contributos para a Validação da Versão

BMJ Open

2 3 4	416	Portuguesa do EQ-5D. Acta Med Port. 2013;26: 664.
5 6 7	417	25. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A,
8 9	418	Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess
10 11 12	419	rhinitis and asthma in patients with asthma. Allergy. 2010;65: 1042–1048.
13 14	420	26. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et
15 16	421	al. Standardization of Spirometry 2019 Update. An Official American Thoracic
17 18	422	Society and European Respiratory Society Technical Statement. Am J Respir Crit
19 20	423	Care Med. 2019;200: e70–e88.
21 22	424	27 Duraik DA Dagge DD Emurum CC Invin CC Laigh MM/ Lundharg IC at al An
23 24	424	27. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An
25 26	425	official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels
27 28	426	(FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184: 602–615.
29 30 31	427	28. Bousquet J, Khaltaev N, Cruz AA: Global surveillance, prevention and control of
32	428	Chronic Respiratory Diseases: A comprehensive approach. Switzerland: World
33 34 35	429	Health Organization; 2007.
36 37 38	430	29. Global Asthma Network. The Global Asthma Report 2018. Auckland, New
39 40 41	431	Zealand: 2018.
42 43	432	30. Pavlović, K. B., Berić, I., & Berezljev, L. AGILE TRANSFORMATION IN CLINICAL
44 45 46	433	RESEARCH. European Project Management Journal. 2018;8: 65–70.
47 48	434	
49 50 51	435	Figures
52 53 54	436	Figure 1: Flow of participants through study's stages. SuA - severe and difficult to treat
55	437	asthma.
56 57		
58 59		
60		






Figure 1: Flow of participants through study's stages. SuA - severe and difficult to treat asthma.

62x57mm (300 x 300 DPI)

BMJ Open

EPI-ASTHMA study protocol - a population-based multicentre stepwise study on the prevalence and characterisation of patients with asthma according to disease severity in Portugal

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-064538.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Aug-2022
Complete List of Authors:	Jácome, Cristina; Center for Health Technology and Services Research Brito, Dinis; USF 7fontes João, Catarina; University of Porto, Lopes, Filipa; MEDIDA Santos, Janete; Center for Health Technology and Services Research Amorim, Liliana; Digital Medicine Center P5 Barbosa, Maria João; University of Minho; Gualtar Family Health Unit Pardal, Marisa; AstraZeneca Teixeira, Pedro; University of Minho - Gualtar Campus, Bernardo, Filipa; AstraZeneca Fonseca, Joao A.; University of Porto Correia-de-Sousa, Jaime; Life and Health Sciences Research Institute (ICVS)/3B's — PT Government Associate Laboratory, University of Minho; Horizonte Family Health Unit,
Primary Subject Heading :	Respiratory medicine
Secondary Subject Heading:	Research methods
Keywords:	Asthma < THORACIC MEDICINE, EPIDEMIOLOGY, Chronic airways disease < THORACIC MEDICINE

SCHOLARONE[™] Manuscripts

3		
4 5	1	EPI-ASTHMA study protocol - a population-based multicentre stepwise study on
6 7	2	the prevalence and characterisation of patients with asthma according to
8 9	3	disease severity in Portugal
10 11	4	Cristina Jácome ^{1,2} , Dinis Brito ^{3,4} Catarina João ¹ , Filipa Lopes ⁵ , Janete Santos ¹ , Liliana
12 13	5	Amorim ⁶ , Maria João Barbosa ^{3,9} , Marisa Pardal ⁷ , Pedro Teixeira ^{3,6} , Filipa Bernardo ⁷ ,
14 15	6	João Almeida Fonseca ^{1,2,5,8} , Jaime Correia de Sousa ³
16 17	7	
18 19 20	8	Affiliations:
21 22	9	1- Center for Health Technology and Services Research (CINTESIS), Faculty of
23 24 25	10	Medicine, University of Porto, Porto, Portugal;
26 27	11	2- Department of Community Medicine, Information and Health Decision Sciences
28 29 30	12	(MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal
31 32	13	3- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of
33 34 35	14	Minho, Braga, Portugal
36 37 38	15	4- Sete Fontes, Family Health Unit, Braga, Portugal
39 40	16	5- MEDIDA, Porto, Portugal
41 42 43	17	6- Digital Medicine Center P5, Braga, Portugal
44 45 46	18	7- AstraZeneca, Queluz, Lisboa, Portugal
47 48 49	19	8- Allergy Unit, Hospital and Institute CUF, Porto, Portugal
50 51	20	9-Gualtar Family Health Unit, Braga, Portugal
52 53 54	21	Corresponding author: Cristina Jácome; Center for Health Technology and Services
54 55 56	22	Research (CINTESIS), Department of Community Medicine, Information and Health
57 58	23	Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Portugal; e-
59 60	24	mail: cristinajacome.ft@gmail.com

25	
26	ABSTRACT
27	Introduction: In Portugal as in other countries, data on the epidemiology of asthma are
28	mainly grounded in questionnaire studies. Additionally, the detailed characterisation of
29	asthma in terms of disease severity, control and phenotypes remain scarce. Studies
30	assessing the prevalence of asthma and its sub-groups using accurate methods are
31	needed. This study aims to determine the prevalence of asthma, difficult-to-treat and
32	severe asthma, and to evaluate sociodemographic and clinical characteristics of those
33	patients, in mainland Portugal.
34	Methods and analysis: A population-based nationwide study with a multicentre
35	stepwise approach will be conducted between 2021-2023 in 38 primary care centres of
36	the Portuguese National Health Service. The stepwise approach will comprise 4 Stages:
37	Stage 0-telephone call invitation to adult subjects (≥18 years) randomly selected
38	(n~15000); Stage 1-telephone screening interview assessing the participants' respiratory
39	symptoms (n~7500); Stage 2- diagnostic visit, including physical examination, diagnostic
40	tests (e.g., spirometry, fraction of exhaled nitric oxide, blood eosinophil count), and
41	patient-reported outcome measures for diagnostic confirmation of those identified with
42	possible asthma at Stage 1 (n~1800); Stage 3-further evaluation of patients with asthma
43	and of patients with difficult-to-treat asthma and severe asthma, after 3 months (n~460).
44	At Stage 3, data will be collected from a review of the patient's electronic health records,
45	a follow-up telephone call and the CARATm app database. The prevalence of asthma,
46	difficult-to-treat and severe asthma will be determined as the percentage of patients with
47	asthma confirmed from the overall population (Stage 1). For the analysis of factors
48	associated with asthma, difficult-to-treat and severe asthma, logistic regression models
49	will be explored.

BMJ Open

2 3 4	50	Ethics and dissemination: Ethical approvals for the study were obtained from the ethics
5	51	committee of the local health unit of Matosinhos, Porto (38/CES/JAS), Alto Minho
7 8	52	(38/2021/CES) and the regional health administration of Lisbon-Vale do Tejo
9 10	53	(035/CES/INV/2021). Results will be published in peer-reviewed journals.
11 12	54	
13 14 15	55	Trial registration: ClinicalTrials.gov, NCT05169619. Registered on December 27th 2021.
16 17	56	
18 19 20 21	57	Strengths and limitations of this study
22 23	58	- The design of this study is based on a stepwise approach, divided in 4 stages,
24 25	59	that mimics the clinical practice diagnostic pathway for asthma.
26 27	60	- This study allows a reliable diagnosis and characterization of asthma patients
28 29	61	through the use of questionnaires together with clinical examination that includes
30 31	62	lung function assessment.
32 33	63	- A mHealth application to engage patients on self-management of their disease
34 35	64	and to improve completeness of the data collection is used.
36 37 38	65	- The 3-month follow-up with lack of optimised management might be a source of
39 40	66	error in the estimation of the prevalence of asthma sub-groups.
41 42	67	- Heterogeneity in data collection across the country regions may prove
43 44	68	challenging and a possible source of bias.
45 46 47	69	Keywords: disease severity, severe asthma, difficult-to-treat asthma, epidemiology
48 49 50	70	
51 52	71	
53 54 55	72	
56 57 58	73	
59 60	74	

75 Introduction

Asthma is a common chronic disease affecting all age groups. Worldwide, it is estimated that about 5 to 10% of people have asthma [1], with a significant wide variation across regions and countries [2]. To date, epidemiological data on prevalence have used heterogeneous methodologies due to difficulties in defining and diagnosing asthma, leading to highly variable estimates of asthma prevalence [3]. Some studies used non-standardised questionnaires, others included participants based on the assessment of lung function or responsiveness to bronchodilators. In Portugal, the 2011 National Asthma Survey was based on telephone interviews and indicated a prevalence of 6.8% [4]. Yet, previous studies have estimated a prevalence between 3.3 and 15% [5]. Furthermore, similarly to the USA and Denmark Asthma Surveys, the 2005-2006 Portuguese Health Survey, suggested that there is an underdiagnosis of asthma, particularly in the male population and in the country's southern regions [5]. The Portuguese National Program for Respiratory Diseases maintains strategic research objectives in epidemiological surveillance both in asthma prevalence and its underdiagnosis [6], which is in line with the recommendations from the Global Initiative for Asthma (GINA) [7].

Additionally, national data on the characterisation of patients with asthma, in terms of severity and control, remain lacking [8]. Worldwide, it is estimated that up to 17% of patients have difficult-to-treat and 3.7% have severe asthma [9], which are more likely to experience life-threatening exacerbations and consume additional healthcare resources. It is important to differentiate these severity groups, as difficult-to-treat asthma might be manageable in primary health care, eventually with concomitant support from a secondary care specialist, whereas severe asthma requires a specialised second or tertiary care approach [10]. Knowledge on the distribution of severity and characteristics of patients in each group will better support clinical management of the disease and will

BMJ Open

inform personalised health policies for a future and smarter allocation of healthcareresources.

The primary aim of this study is to determine the prevalence of asthma, difficult-to-treat and severe asthma in Portugal. The secondary aims are to evaluate the sociodemographic and clinical characteristics of patients with asthma.

108 METHODS AND ANALYSIS

109 Patient and Public Involvement

110 No patient involved

111 Study Design

EPI-ASTHMA is a population-based, nationwide, cross-sectional, prevalence study. This study will be conducted between 2021 and 2023, and will involve 38 primary care centres (PCC) of the Portuguese National Health Service (NHS), geographically distributed across all mainland Portugal Health Regions (North, Centre, Lisbon Metropolitan Area, Alentejo and Algarve). The study will be conducted using a stepwise approach parallel to a clinical practice diagnostic methodology. Firstly, subjects will be invited for a screening telephone interview to report respiratory symptoms, those who fulfil the eligible criteria will be invited for a clinical assessment in a mobile outpatient clinic. A sub-group of participants with confirmed asthma diagnosis will have a follow-up after 3 months for characterization of their asthma profile, symptoms patterns, clinical features, and treatment patterns. EPI-ASTHMA was first piloted in one local health unit located in the North region from May to October 2021, where all study procedures were tested; after which, implementation is planned to follow the order of approval of the ethics committee from each local health unit and regional health administrations. Currently, the study has been concluded in 4 PCC in Northern Portugal.

This study protocol is described according to STROBE (The Strengthening the Reporting
of Observational Studies in Epidemiology Statement: guidelines for reporting
observational studies) statement [11].

131 Study population and sample size

132 Sample size was estimated using Cochran's formula [12]:

 $n = \frac{Z^2 P(1-P)}{d^2}$ (1)

Where *n* is the sample size, *Z* is the statistic corresponding to level of confidence, *P* is expected prevalence of Severe Asthma, and d is the desired level of precision (i.e. the margin of error). Applying a Z = 1.96 (i.e. 95% confidence interval), an estimated prevalence in the population of P = 0.42% and a margin of error of 0.15% the estimated sample size is 7141. In order to obtain 7500 participants on screening we consider a stepwise approach with a 50% dropout on invitation. Therefore, around 15000 adults will be randomly selected from the Portuguese NHS database to be contacted and invited to enrol in the study. In Portugal, the majority of the population (including Portuguese nationals and legal residents) is registered in a PCC, therefore the NHS database includes almost the entire resident population in the local administrative entity (i.e., Nomenclature of Territorial Units for Statistics-NUTS). The sample stratification was based on demographic stratification NUTS III, small regions for specific diagnoses as per EUROSTAT classification. For each NUTS III, the PCC were selected according to the feasibility of implementing the study (in total 38 PCC, 31 are part of the regional health administrations and 7 of local health units). The number of participants will be randomly selected according to the proportional allocation of each PCC. The distribution of an estimated stratified sample by NUTS III and the correspondent study Stages is presented in Table 1. The study will include male or female subjects with at least 18 years old, registered in the NHS database, who give voluntary consent. Subjects with

BMJ Open

any specific physical and/or cognitive disabilities that prevented them from cooperating
with the study procedures (e.g., lung function tests) and/or understanding/answering
self-reported questionnaires will be excluded.

157 Table 1 – Distribution of the estimated stratified sample [13].

NUTS III	Population	Primary	Stage 0	Stage 1	Stage 2	Stage 3
		care	(0.15%)	(50%)	(24%)	(25%)
		centres				
Alto Minho/Cávado	637305	2	975	488	118	30
Ave	414763	2	635	317	77	19
Área Metropolitana do	1719362	6	2631	1316	319	81
Porto						
Alto Tâmega/Douro/Terras	389151	2	596	298	72	18
de Trás-os-Montes						
Tâmega e Sousa	419811	2	643	321	78	20
Oeste	357868	2	548	274	66	17
Região de Aveiro	363424	2	556	278	67	17
Região de Coimbra	438228	2	671	335	81	21
Região de Leiria	287040	1	439	220	53	13
Viseu Dão	555628	2	850	425	103	26
Lafões/Beiras/Serra da						
Estrela/Beira Baixa						
Médio Tejo/Lezíria do Tejo	474802	2	727	363	88	22
Área Metropolitana de	2827514	9	4328	2164	525	133
Lisboa						
Alentejo Litoral/Baixo	475674	2	728	364	88	22
Alentejo/Alto Alentejo/						
Alentejo Central						
Algarve	440543	2	674	337	82	21
Total	9801113	38	15000	7500	1819	460



NUTS - Nomenclature of Territorial Units for Statistics.

4 5	
5 6 7 8 9 10 11 12 13 14 15 16 17 18	
8 9	
10 11 12	
13 14	
15 16	
17 18	
19	
21 22 23	
24 25	
20 21 22 23 24 25 26 27 28	
28 29 30	
21	
32 33 34 35 36 37 38	
35 36 37	
38 39	
40 41	
42 43 44	
44 45 46	
47 48	
49 50	
51 52 53	
55 55	
56 57	
58 59	
60	

164

165

1 2 3

159 Study procedures

160 EPI-ASTHMA will use a stepwise approach, sequentially comprising the evaluation of 161 symptoms patterns, clinical features, and tests for diagnosis confirmation, that includes 162 the following stages (Figure 1):

- **Stage 0- Study enrolment**: Telephone call invitation to enrol participants;
 - Stage 1- Screening interview: Telephone call interview to assess respiratory symptoms;
- Stage 2- Diagnostic visit: Clinical assessment, diagnostic confirmation and
 patient characterization;
- Stage 3- Sub-group asthma characterization: follow-up of patients with
 asthma (sub-group) and of patients with difficult-to-treat asthma and severe
 asthma, after 3 months.
- 171 Stage 0- Study enrolment

Around 15,000 randomised subjects 18 years or above will receive a telephone call 172 173 invitation for enrolment in the study, to secure a sample size of 7500 participants for the 174 next stage (assuming an acceptance of 50%) [14]. If needed, a second round of 175 telephone calls will also be made to complete the number of patients in each region. 176 Trained clinical secretaries will conduct this stage by following a semi-structured guide during the telephone call. A screening log of potential eligible participants will be 177 178 completed to document the main reasons for participants not entering the study. Subjects 179 who fulfil the study eligibility criteria and give their oral consent will be contacted in Stage 1. 180

2 181 Stage 1- Screening interview

182 A computer-assisted telephone screening interview will be performed to 7500 183 participants. The interview will include validated patient-reported outcome measures for 184 screening asthma [15] and chronic obstructive pulmonary disease (COPD) [16],

BMJ Open

dyspnoea [17] and assessment of physical activity [18,19], among other questions formulated by the researchers (Table 2). At this stage participants will be considered eligible and invited to participate in Stage 2 if they have, at least, one positive response in the Adult Asthma Score (A2 Score) [15], i.e., medical history of asthma or asthma medication intake or asthma symptoms. For quality control, 5% of not eligible participants (with a negative score) will also be invited to participate in Stage 2. Interviews will be performed by a centralised team of trained and experienced interviewers. Each participant will be contacted for at least ten attempts during different occasions before being considered excluded. Prior to any question, participants will be asked to reinforce their oral consent to participate. A pilot study with 12 individuals was conducted to assess the clarity and feasibility of the screening interview before starting the data collection [20]. The duration of each interview was no longer than 17 minutes.

197 Stage 2 – Diagnostic visit

The diagnostic visit will be conducted in a mobile outpatient clinic, located, whenever possible, in the close vicinity of each PCC. At this stage, participants will give a written informed consent before any study-related procedures. Stage 2 is expected to include 1800 participants, about 20% of participants from Stage 1 who fulfil the eligibility criteria, plus 5% of participants for quality control. A detailed clinical assessment will be performed, including clinical history, physical examination, lung function tests, blood count and inflammatory biomarkers testing and patient-reported outcome measures (Table 2). The clinical assessment will be carried out by a physician and the diagnostic tests by an experienced team to assure the quality and the harmonisation of procedures. All patients will be provided with a letter addressed to their primary care physician, containing the results of their clinical evaluation. Patients with asthma will also be invited to install and use the CARATm app ("Caracteristicas Auto-reportadas de Asma em Tecnologias Móveis") in their daily life. CARATm is a Portuguese health mobile app developed to collect clinical data from patients with asthma, such as asthma control and

212 medication adherence, which is also interoperable with the Portuguese Severe Asthma213 Registry (asmagrave.pt).

215 Stage 3- Sub-group asthma characterization

Table 2.

This stage is expected to include 460 participants: a randomised sample of patients with asthma, and all patients identified with difficult-to-treat or severe asthma. Patients with difficult-to-treat and severe asthma will be defined according to GINA[21]. This stage takes place 3-months after the diagnostic visit and consists of a review of patients' electronic health records, a follow-up telephone call to the patient, and extraction of CARATm app data. The review of patients' electronic health records by a physician of their PCC will ensure an asthma control assessment on two different time points, and will confirm the treatment profile for an adequate GINA severity classification [7] (Table 2).

Summary of the data collection per study's stage.

	Stage 1	Stage 2	Stage 3	-
Sociodemographic and anthropometric characteristics	×			-
Brief PA assessment	×	×		
Respiratory symptoms (wheeze, breathlessness)	×	×	×	
CAPTURE	×			
mMRC	×			
Diagnosis of chronic respiratory disease	×	×	×	
Comorbidities and allergies	×	×	×	
Smoking habits and ETS	×	×		
A2 Score	×			
Family history of asthma	×	×		
Age of asthma onset		×		
Inhaler prescription/use	×			
Mini-AQLQ		×		
EQ-5D		×		

2				
3	Signs of asthma		×	
4	CARAT		×	×
5	CARAT		^	^
6	Asthma control (according to GINA)		×	×
7	Asthma pharmacological treatment		×	×*
8			~	~
9	Inhalation technique		×	
10	Adherence to inhaled medication		×	×*
11	Adherence to initiated medication		^	^
12	Other treatments		×	×
13	Number of exacerbations		×	×*
14			^	^
15	Number of visits to emergency room		×	×*
16	Number of hospital admissions and length of hospital stay		×	×*
17	Number of nospital admissions and length of nospital stay		^	^
18	Number of unscheduled consultations		×	×*
19	Number of consultations primary care team		×	×*
20 21	Number of consultations primary care team		~	~
22	Referral for specialist care		×	×*
23	Standard measurements (blood pressure, height, weight)		×	
24				
25	Pre-BD and post-BD lung function		×	
26	Pulmonary diagnostic tests (previously performed)			×
27				
28	FeNO		×	
29	Peripheral blood eosinophil and neutrophil counts		×	
30				
31	Use of health and fitness apps	×	×	
32	CARATm app use and opinion			×
33				
34	A2 Score = A2 adult asthma score[15]; CAPTURE = COPD Assessme	ent in Primary Car	e to Identify Und	agnosed
35	Respiratory Disease and Exacerbation Risk [16]; mMRC = Modified Brit	sh Medical Resea	rch Council [17];P	A = Brief

ief physical activity assessment [18,19]; ETS = Environmental tobacco smoke; Mini-AQLQ = Mini Asthma Quality of Life Questionnaire[22,23]; EQ-5D = European Quality of Life Five Dimension [24]; CARAT = Control of Allergic Rhinitis and Asthma Test [25]; pre-BD and post-BD=Spirometry pre- and post-bronchodilator [26]; FeNO = Fractional exhaled nitric oxide [27]; || *In the previous 3 and 12 months.

Diagnosis criteria and definitions

According to GINA, uncontrolled asthma includes one or both of the following: poor symptom control and frequent exacerbations (≥ 2 /year) requiring oral corticosteroids, or serious exacerbations (≥1/year) requiring hospitalisation [21]. In our study, poor symptom control will be based on a score less or equal than 24 in the Control of Allergic Rhinitis and Asthma Test (CARAT) [25, 28]. Data regarding exacerbations or serious exacerbations will be collected at stage 2 and 3.

Difficult-to-treat asthma is asthma that is uncontrolled despite treatment with medium or high dose inhaled corticosteroids with a second controller or with maintenance oral corticosteroids, or that requires high dose treatment to maintain symptom control and to reduce the risk of exacerbations [21]. In our study, difficult-to-treat asthma will be defined as uncontrolled asthma, despite prescription of high intensity treatment (GINA step treatment 4-5). Severe asthma is a subset of difficult-to-treat asthma, that is an uncontrolled asthma despite adherence with maximal optimised high dose ICS-LABA (inhaled corticosteroid and a long-acting β 2-agonist) treatment and management of contributory factors, such as inhaler adherence and technique or asthma that worsens when high dose treatment is decreased. We will define severe asthma in the study as uncontrolled asthma despite prescription of high intensity treatment (GINA step treatment 4-5), and good treatment adherence (visual analogue scale (VAS) \geq 50) [29] and good inhaler technique (number of critical errors = [0-1]) [30]. Data storage, blinding and statistical analysis plan Participants will be anonymized with a unique subject ID and their data will be anonymously stored in an appropriately secured server. In order to minimise diagnostic bias, researchers, data collectors and participants will be blinded to patient eligibility throughout data collection during Stage 2. Over the stages, data will be collected for a

255 secondary data).

Statistical analysis will allow the characterization of the study population and the estimation of each study's endpoints. The prevalence of asthma, difficult-to-treat and severe asthma with the respective 95% confidence intervals (95% CI) will be calculated in relation to the entire study population (Stage 1). Descriptive statistics such as i) central tendency (e.g. mode, median or mean); ii) localisation (e.g. percentile); iii) dispersion (e.g. interguartile range, standard deviation) and iv) distribution (e.g. skewness, kurtosis) will be used, depending on the type of each variable, to characterise the total sample or

specific electronic case report form (e-CRF) by using blended data (primary and

Page 13 of 22

BMJ Open

subgroups. Associations between two quantitative variables will be calculated using the Pearson's correlation coefficient or Spearman correlation coefficient, in case of normality assumption are not verified. Association of two categorical variables will be determined using the Chi-Square test or Fisher Exact test. Continuous variables between two groups will be compared with a t-test for independent samples or Mann-Whitney test, whereas for comparisons among 3 or more groups an ANOVA or Kruskall-Wallis test will be used. Null-hypothesis statistical testing will also be applied in an exploratory manner to identify any relationship patterns among variables. Subgroup analysis per each asthma control level, GINA treatment step, Short-Acting Beta Agonists (SABA) overuse among others, will also be conducted. Measurements of effect size will be presented and confidence intervals at 95% will be estimated to account for the uncertainty of the sample estimates. Interim analysis will be conducted per region after all stages are completed to monitor the safety of study procedures and completeness of data collection. This analysis may encompass potential changes in logistical, monitoring, and recruitment procedures to secure sample size.

For the analysis of factors associated with asthma, difficult-to-treat asthma and severe asthma, logistic regression models will be explored, taking into consideration these as dependent variables and sociodemographic, clinical, among other variables, as independent variables. The variables to be included in the multivariate model will be selected from the univariate analyses, when p-value <0.100, those that do not meet these criteria, but are considered clinically relevant, will also be possible candidates. The final model will be analysed from two perspectives: 1) the calibration using the Hosmer-Lemeshow goodness of fit test, and 2) the discrimination, using ROC curves and the respective area under the curve. All results will be considered statistically significant when p-value < 0.05.

DISCUSSION

 The EPI-ASTHMA study will address knowledge gaps in the epidemiology and characterisation of asthma in mainland Portugal, using a multicentre approach that combines different data collection methods, including a mHealth solution. Furthermore, it will provide a more complete picture of the prevalence of difficult-to-treat and severe asthma in Portugal, and will allow a better understanding of these patients' characteristics, treatment profile and healthcare resource use. Further knowledge on the distribution of severity and characteristics of patients in each group will better support clinical management of the disease and inform personalised health policies for a smarter allocation of the needed healthcare resources. This ambitious study is aligned with the global need of epidemiological studies to monitor the trends in the prevalence of asthma, which is vital to ensure that health policies fit the populations' needs [2,31,32].

The study design is one of its strengths. The combination of standardised questionnaires with a standardised clinical evaluation, including lung function tests will allow a more accurate diagnosis and characterisation of asthma. However, few limitations and potential risks must be acknowledged. The definition of difficult-to-treat and severe asthma will be based on the GINA treatment steps (4-5) and the assessment of asthma control during the study Stages 2 and 3, which is only 3-months apart. An optimised management during the follow-up period was not included, which is also part of the GINA criteria to distinguish these asthma subgroups. This will probably be a source of error in the estimation of the prevalence of these sub-groups, linked to the observational nature of this study. The 38 PCC will be conveniently selected, which can be seen as a source of bias. Yet, we considered the geographic areas and population distribution of each Portuguese region as well as their interest to participate and willingness to collect data and not only based on previous asthma research experience which will preserve the study real-world nature. Clinical secretaries (Stage 0) and physicians (Stage 2 and 3)

Page 15 of 22

BMJ Open

will collaborate across different country's regions, which may introduce some heterogeneity in data collection. Nevertheless, both clinical secretaries and physicians will be previously trained and continuously motivated by the management team, which will be available to clarify doubts on a 24/7 basis. To deal with possible risks, the study's steering committee will supervise the execution and will take academic responsibility for the study. Another limitation is the need for this multicentre study to be approved by the ethics committees responsible for each regional health administration/local health unit. Although all applications will be similar in their content, they will differ in a number of aspects to comply with each institution's formal requirements, resulting in additional complexity and may hinder the compliance with the study timeline. To mitigate these risks, an experienced contracted research organisation that knows the specificities of each administration/health unit is supporting us through all the process.

EPI-ASTHMA will be managed combining traditional management methodologies with
 an "agile" approach [33] using the SCRUM framework on Jira software. This combination
 is expected to fulfil the need to make the study adaptable and to anticipate future needs
 that are important and can be forgotten due to the dimension of the study.

332 Conclusion

EPI-ASTHMA will be the first population-based study in Portugal to determine the prevalence of asthma, difficult-to-treat and severe asthma and to better understand the patient's disease characteristics, treatment patterns and use of healthcare resources. The knowledge generated by this nationwide robust study has great potential to inform health policies and to improve the clinical outcomes of patients with asthma in Portugal.

Ethics and dissemination:

340 The study will follow the tenants of the Declaration of Helsinki and the Oviedo 341 Convention. Ethical approvals and data privacy clearance for the study were obtained 342 by the Ethics Committee and Data Protection Officer of the local health unit of

Matosinhos, Porto (ULSM; 38/CES/JAS, March 12th ,2021), Alto Minho (ULSAM; 38/2021/CES, June 17th, 2021) and the Regional Health Administration of Lisbon and Vale do Tejo (ARSLVT; 035/CES/INV/2021; December 3rd 2021) and is under revision in the remain regional ethical committees for health administration/local health units. All participants will receive both verbal and written information explaining the purpose of the study and they will have to provide verbal and written informed consent. Results will be presented at both national and international scientific meetings and published in peer-reviewed journals. Seasonal newsletters will be provided to the funders of the study as well as all the involved participants.

Statements

blication Patient consent for publication

Not applicable.

Authors' contributions

Jaime Correia de Sousa, João Almeida Fonseca and Filipa Bernardo conceptualised the study. Cristina Jácome wrote the statistical analysis plan and Pedro Teixeira conducted the sample size calculation. Cristina Jácome and Catarina João wrote the first draft of the manuscript. Cristina Jácome, Dinis Brito, Catarina João, Filipa Lopes, Janete Santos, Liliana Amorim, Maria João Barbosa, Marisa Pardal, Pedro Teixeira, Filipa Bernardo, João Almeida Fonseca, Jaime Correia de Sousa contributed to and refined the manuscript for scientific content. All authors read and approved the final version of the manuscript.

Competing interests

BMJ Open


3 4 5	3
6 7	3
8 9	3
10 11	3
12 13	3
14 15	3
16 17	3
18 19	3
20 21	3
22 23	3
24 25	3
26 27 28	3
29 30	3
31 32 33	3
34 35 36	3
37 38 39 40 41	3 3 3
41 42 43 44	3 3
45 46 47 48	3 3 3
49 50 51 52	3 3 3
53 54 55	3 3
56 57 58	3 3
59 60	3 3

JCS reports Advisory Board from Boheringer Ingelheim, personal fees and Advisory 368 69 Board from GSK, grants, personal fees and Advisory Board from AstraZeneca, personal 70 fees and Advisory Board from Bial, non-financial support from Mundipharma, personal 71 fees from Sanofi, Advisory Board from Novartis, outside the submitted work. JAF 72 declares grants from or research agreements with AstraZeneca, Mundipharma, Sanofi Regeneron and Novartis. Personal fees for lectures and attending advisory boards from 73 74 AstraZeneca, GSK, Mundipharma, Novartis, Sanofi Regeneron and TEVA. MP and FB 75 are employees of AstraZeneca, Produtos Farmacêuticos. The remaining authors declare 76 no conflicts of interest. 77 Funding 78 79 Funding for this study was provided by AstraZeneca. The funding body had no role in the conducting or reporting of the study. N/A for the award/grant number. 80 J.L. 81 82 REFERENCES Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International 83 1. ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur 84 Respir J. 2014;43: 343-373. 85 2. Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma 86 prevalence. Eur Respir J. 2020;56. doi:10.1183/13993003.02094-2020 87 88 3. Sá-Sousa A, Jacinto T, Azevedo LF, Morais-Almeida M, Robalo-Cordeiro C,

- Bugalho-Almeida A, et al. Operational definitions of asthma in recent
 epidemiological studies are inconsistent. Clin Transl Allergy. 2014;4: 24.
- ⁹ 391 4. Sa-Sousa A, Morais-Almeida M, Azevedo LF, Carvalho R, Jacinto T, Todo-Bom A,
 ⁹ 392 et al. Prevalence of asthma in Portugal The Portuguese National Asthma Survey.
 ¹ 393 Clin Transl Allergy. 2012;2: 15.
- 3945.de Sousa JC, Santo ME, Colaço T, Almada-Lobo F, Yaphe J. Asthma in an urban395population in Portugal: a prevalence study. BMC Public Health. 2011;11: 347.
- ⁶ 396 6. da Saúde D-G. Programa Nacional para as Doenças Respiratórias 2017. Lisboa:
 ⁷ 397 Direção-Geral da Saúde; 2017.
- ⁵⁹ 398 7. Global Initiative for Asthma. Global Strategy for Asthma Management and
 ⁵⁰ 399 Prevention. 2021.

1			
2			
3	400	8.	Sá-Sousa A, Amaral R, Morais-Almeida M, Araújo L, Azevedo LF, Bugalho-
4	401		Almeida A, et al. Asthma control in the Portuguese National Asthma Survey. Rev
5	402		Port Pneumol. 2015;21: 209–213.
6 7	400	~	News inches 14 Difficult to Taget and Occurry Actives Management Otestavian Are
8	403	9.	Narasimhan K. Difficult to Treat and Severe Asthma: Management Strategies. Am
9	404		Fam Physician. 2021;103: 286–290.
10	405	10.	Ryan D, Murphy A, Ställberg B, Baxter N, Heaney LG. "SIMPLES": a structured
11	406	-	primary care approach to adults with difficult asthma. Prim Care Respir J. 2013;22:
12	407		365–373.
13 14			
15	408	11.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et
16	409		al. The Strengthening the Reporting of Observational Studies in Epidemiology
17	410 411		(STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18: 800–804.
18	411		Epiderniology. 2007, 10. 000-004.
19 20	412	12.	Kasiulevičius V, Šapoka V, Filipavičiūtė R. Sample size calculation in
20 21	413		epidemiological studies. Gerontologija. 2006;7: 225–231.
22			
23	414	13.	Instituto Nacional de Estatística. Censos 2011. XV Recenseamento Geral da
24	415		População : V Recenseamento Geral da Habitação. Resultados definitivos :
25	416 417		Portugal. Lisboa : INE, 2012. IV Recenseamento Geral de Habitação. Lisboa, Portugal: Instituto Nacional de; 2012.
26	417		
27 28	418	14.	Lopes C, Torres D, Oliveira A, Severo M, Alarcão V, Guiomar S, et al. Inquérito
29	419		Alimentar Nacional e de Atividade Física IAN-AF 2015-2016: relatório de
30	420		resultados. 2017. Available:
31	421		https://repositorioaberto.up.pt/bitstream/10216/111073/2/257104.pdf
32	422	15	Sá-Sousa A, Pereira AM, Almeida R, Araújo L, Couto M, Jacinto T, et al. Adult
33	422	15.	Asthma Scores-Development and Validation of Multivariable Scores to Identify
34 35	424		Asthma in Surveys. J Allergy Clin Immunol Pract. 2019;7: 183–190.e6.
36			
37	425	16.	Martinez FJ, Mannino D, Leidy NK, Malley KG, Bacci ED, Barr RG, et al. A New
38	426		Approach for Identifying Patients with Undiagnosed Chronic Obstructive
39	427		Pulmonary Disease. Am J Respir Crit Care Med. 2017;195: 748–756.
40 41	428	17	Standardized Questionaries on Respiratory Symptoms. Br Med J. 1960;2: 1665–
41	428	17.	1665.
43			
44	430	18.	Cruz J, Jácome C, Oliveira A, Paixão C, Rebelo P, Flora S, et al. Construct validity
45	431		of the brief physical activity assessment tool for clinical use in COPD. Clin Respir
46	432		J. 2021;15: 530–539.
47 48	422	10	Marshall AL, Smith BJ, Bauman AE, Kaur S. Reliability and validity of a brief
48 49	433 434	19.	physical activity assessment for use by family doctors. Br J Sports Med. 2005;39:
50	434		294–7; discussion 294–7.
51	155		
52	436	20.	van Teijlingen E, Hundley V. The importance of pilot studies. Nurs Stand. 2002;16:
53	437		33–36.
54 55	420	01	Clobal Initiative for Aethma, A new Decket Cuide, "Disgnasis and Management of
55 56	438 439	ΖΊ.	Global Initiative for Asthma. A new Pocket Guide, "Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients." 2021 Apr.
57	439		Dimoun-to-treat and Gevere Astima in addrescent and addit patients. 2021 Apr.
58	440	22.	Ferreira PL, Mendonça C, Newparth N, Mata p, Juniper EF, Mear I. Quality of life
59	441		in asthma: cultural adaptation of Juniper's AQLQ to Portuguese. 1998. p. 7 (7):
60	442		590.

1		
2 3 44 4 44 5		Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14: 32–38.
6 44 7 44 8		Ferreira PL, Ferreira LN, Pereira LN. Contributos para a Validação da Versão Portuguesa do EQ-5D. Acta Med Port. 2013;26: 664.
9 44 10 44 11 44	8	Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A, Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy. 2010;65: 1042–1048.
12 13 45 14 45 15 45 16 45 17 45	1 2	Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200: e70–e88.
1845194520452145	5	Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184: 602–615.
22 23 24 25 26 45 45 45 26	8 9	Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Sa-Sousa A, Azevedo LF, Ferreira J, et al. Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time. Clinical and Translational Allergy. 2012. p. 16.
27 28 46 29 46 30 46	2	Ohta K, Jean Bousquet P, Akiyama K, Adachi M, Ichinose M, Ebisawa M, et al. Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan. J Asthma. 2013;50: 514–521.
31 32 46 33 46 34 46	5	Bosnic-Anticevich SZ, Cvetkovski B, Azzi EA, Srour P, Tan R, Kritikos V. Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management. Pulm Ther. 2018;4: 1–12.
35 36 46 37 46		Bousquet J W. Global surveillance, prevention and control of chronic respiratory diseases : a comprehensive approach. 2007
38 39 46 40 47		Global Asthma Network. The Global Asthma Report 2018. Auckland, New Zealand: 2018.
41 42 47 43 47		Pavlović, K. B., Berić, I., & Berezljev, L. AGILE TRANSFORMATION IN CLINICAL RESEARCH. European Project Management Journal. 2018;8: 65–70.
44 45 47 46	3	
47 48 47 49	4 Fig	ures
50 51 47	5 Fig	ure 1: Flow of participants through study's stages. SuA - severe and difficult to treat
52 53 47 54 55 56 57 58 59 60	6	asthma.






Figure 1: Flow of participants through study's stages. SuA - severe and difficult to treat asthma.

62x57mm (300 x 300 DPI)

STROBE Statement-	-checklist of items that s	should be included in repor	ts of observational studies

	Item No	Recommendation	Item found on
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the	page 1-2
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			-
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods	<u> </u>
	5	of recruitment, exposure, follow-up, and data collection	/-11
Participants	6	(a) Cross-sectional study—Give the eligibility criteria, and the	7-10
i articipants	0	sources and methods of selection of participants	/ 10
		(b) Cohort study—For matched studies, give matching criteria and	NA
		number of exposed and unexposed	11A
		<i>Case-control study</i> —For matched studies, give matching criteria	
		and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	11 and table 2
	,	confounders, and effect modifiers. Give diagnostic criteria, if	11 und tuble 2
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	
measurement	-	methods of assessment (measurement). Describe comparability of	
mousurement		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	12 and 14
Study size	10	Explain how the study size was arrived at	6-7 and table 1
Quantitative	11	Explain how quantitative variables were handled in the analyses. If	12-13
variables		applicable, describe which groupings were chosen and why	
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control	12-13
		for confounding	
		(b) Describe any methods used to examine subgroups and	12-13
		interactions	
		(c) Explain how missing data were addressed	NA
		(d) Cross-sectional study—If applicable, describe analytical	12-13
		methods taking account of sampling strategy	-
		(<i>e</i>) Describe any sensitivity analyses	NA
		<u> </u>	

Continued on next page

3 4 5 6 7 8 9 10 11 2 13 14 15 16 7 18 19 20 12 22 3 24 25 26 7 28 29 30 13 23 33 33 33 34 41 42 43 44 56 47 48 49 50 15 25 35 45 56 57 58 59 60	2
$\begin{smallmatrix} 5 & 6 & 7 & 8 \\ 9 & 10 & 11 & 21 & 31 & 11 & 11 & 11 & 11 & 11$	3
$egin{array}{cccccccccccccccccccccccccccccccccccc$	4
7 8 9 10 11 21 12 23 33 33 33 34 44	5
9 10 11 12 13 14 15 16 17 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 12 34 45 16 7 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	6
9 10 11 12 13 14 15 16 17 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 12 34 45 16 7 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	7
9 10 11 12 13 14 15 16 17 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 12 34 45 16 7 18 19 20 12 22 32 42 52 27 28 29 30 13 23 34 35 36 7 8 9 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	8
101 12 13 14 15 16 17 18 19 20 22 23 33 34 35 36 7 83 94 44 <td< th=""><th>-</th></td<>	-
$\begin{array}{c} 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\$	
$\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	
$\begin{array}{c} 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 12 \\ 23 \\ 24 \\ 25 \\ 26 \\ 7 \\ 28 \\ 29 \\ 30 \\ 12 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 83 \\ 90 \\ 41 \\ 42 \\ 34 \\ 45 \\ 67 \\ 84 \\ 90 \\ 51 \\ 52 \\ 54 \\ 55 \\ 57 \\ 58 \\ 59 \end{array}$	
$\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 2 \\ 2 \\ 2 \\$	
$\begin{array}{c} 15 \\ 16 \\ 17 \\ 18 \\ 9 \\ 21 \\ 22 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 9 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 37 \\ 38 \\ 9 \\ 41 \\ 42 \\ 34 \\ 45 \\ 46 \\ 47 \\ 48 \\ 9 \\ 51 \\ 52 \\ 54 \\ 55 \\ 57 \\ 58 \\ 59 \end{array}$	
$\begin{array}{c} 1 \ 6 \\ 1 \ 7 \\ 1 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	
17 17 17 17 19 20 21 22 22 22 22 22 22 22 22 22	15
$\begin{array}{c} 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 7\\ 8\\ 9\\ 31\\ 23\\ 33\\ 35\\ 36\\ 37\\ 8\\ 39\\ 41\\ 42\\ 43\\ 44\\ 56\\ 7\\ 8\\ 9\\ 0\\ 51\\ 52\\ 53\\ 55\\ 57\\ 8\\ 59\end{array}$	
$\begin{array}{c} 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 67\\ 28\\ 9\\ 30\\ 1\\ 2\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\$	17
20 21 22 23 24 25 26 27 28 30 31 32 33 34 35 36 37 38 40 41 42 44 45 46 47 48 49 51 52 54 55 57 58 59 50 51 52 54 55 57 58 59 50 51 52 53 54 55 57 58 59 50 51 <th>18</th>	18
$\begin{array}{c} 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 9\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 9\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 9\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 7\\ 58\\ 59\\ \end{array}$	19
$\begin{array}{c} 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 9\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 9\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 9\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 7\\ 58\\ 59\\ \end{array}$	20
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{array}{c} 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 1\\ 2\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 3\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 4\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\$	
$\begin{array}{c} 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 2\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 47\\ 48\\ 90\\ 51\\ 52\\ 53\\ 55\\ 57\\ 58\\ 59\end{array}$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{array}{c} 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 9\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ \end{array}$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{array}{c} 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 90\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ \end{array}$	27
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	29
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	30
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	31
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
3637383940414243444546474849505152535455565758	
37383940414243444546474849505152535455565758	
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	
 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	42
 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	43
 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
 46 47 48 49 50 51 52 53 54 55 56 57 58 59 	
47 48 49 50 51 52 53 54 55 56 57 58 59	
48 49 50 51 52 53 54 55 56 57 58 59	
49 50 51 52 53 54 55 56 57 58 59	
50 51 52 53 54 55 56 57 58 59	
51 52 53 54 55 56 57 58 59	
52 53 54 55 56 57 58 59	
53 54 55 56 57 58 59	
54 55 56 57 58 59	
55 56 57 58 59	
56 57 58 59	
56 57 58 59	55
57 58 59	
58 59	
59	
00	
	00

Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers	NA
		potentially eligible, examined for eligibility, confirmed eligible, included in	
		the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical,	NA
data		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of	NA
		interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total	NA
		amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures	NA
		over time	
		Case-control study—Report numbers in each exposure category, or	NA
		summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary	NA
		measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	NA
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute	NA
		risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and	NA
		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	NA
Limitations	19	Discuss limitations of the study, taking into account sources of potential	14-15
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	NA
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
Other information	on		
Funding	22	Give the source of funding and the role of the funders for the present study	16
	-	and, if applicable, for the original study on which the present article is	-
		based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.